SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Discovery of the Dual Orexin Receptor Antagonist [(7 R )-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia
1 references·13 citing·32 second hop
Discovery of the Dual Orexin Receptor Antagonist [(7 R )-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2 H -1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia (2010)Discovery of the Dual Orexin Receptor Ant…Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents (2008)Insomnia and its relationship…The orexin story and orexin receptor antagonists for the treatment of insomnia (2023)The orexin story and orexin r…Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial (2020)Polysomnographic assessment o…Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders (2020)Clinical pharmacology, effica…Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials (2017)Suvorexant in Elderly Patient…Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials (2016)Suvorexant in Patients with I…Suvorexant: The first orexin receptor antagonist to treat insomnia (2015)Suvorexant: The first orexin …On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers (2015)On-the-Road Driving Performan…Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data (2015)Effects of suvorexant on slee…Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials (2014)Suvorexant in Patients With I…Suvorexant for the treatment of insomnia (2014)Suvorexant for the treatment …Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? (2014)Suvorexant for insomnia: a sy…Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men (2013)Effects of Suvorexant, an Ore…Orexin receptor antagonism for treatment of insomnia (2012)Orexin receptor antagonism fo…Validation of the Insomnia Severity Index as an outcome measure for insomnia research (2001)Epidemiology of insomnia: what we know and what we still need to learn (2002)Diagnostic and Statistical Manual of Mental Disorders (2013)Advances in the management of chronic insomnia (2016)Sleep Medicine: Insomnia and Sleep. (2019)Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder (2020)A manual for standardized terminology, techniques and scoring system for sleep stages in human subjects (1968)The use of analogue scales in rating subjective feelings (1974)Subjective and Objective Sleepiness in the Active Individual (1990)The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults (2011)Diagnostic and Statistical Manual of Mental Disorders (2013)Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians (2016)The assessment and management of insomnia: an update (2019)Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (2022)The American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications (2007)Diagnostic and Statistical Manual of Mental Disorders ( DSM ‐ IV ‐ TR ) (2010)Diagnostic and Statistical Manual of Mental Disorders. (2000)Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies (2021)The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research (1989)Methods for the Economic Evaluation of Health Care Programmes (2005)Sleep disorders and work performance: findings from the 2008 National Sleep Foundation Sleep in America poll (2010)Societal costs of insomnia (2010)Trends in insomnia and excessive daytime sleepiness among US adults from 2002 to 2012 (2015)The clinical global impressions scale: applying a research tool in clinical practice. (2007)Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017)Pharmacological and non‐pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review (2020)Pharmacotherapies for sleep disturbances in dementia (2020)Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders (1989)Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? (1989)International Classification of Sleep Disorders-Third Edition (2014)Diagnostic and Statistical Manual of Mental Disorders (2022)Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations (2023)
this work references cited by second hop

References

  • 2008Insomnia and its relationship to health-care utilization, work absenteeism, productivity and accidents441 cited

Cited by

  • 2012Orexin receptor antagonism for treatment of insomnia322 cited
  • 2014Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials301 cited
  • 2014Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?250 cited
  • 2020Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial194 cited
  • 2013Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men162 cited
  • 2023The orexin story and orexin receptor antagonists for the treatment of insomnia119 cited
  • 2020Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders102 cited
  • 2016Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials87 cited
  • 2015Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data79 cited
  • 2015On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers76 cited
  • 2017Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

75 cited
  • 2015Suvorexant: The first orexin receptor antagonist to treat insomnia70 cited
  • 2014Suvorexant for the treatment of insomnia59 cited